Literature DB >> 33910375

HLA-A*24:07 as a potential biomarker for carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Filipino patients.

Francis Capule1, Pramote Tragulpiankit2, Surakameth Mahasirimongkol3, Jiraphun Jittikoon4, Nuanjun Wichukchinda3, Lara Theresa Alentajan-Aleta5, Jay-V James Barit6, Josephine Casanova-Gutierrez7, Leonor Cabral-Lim7, Jose Paciano Baltazar Reyes7, Francisca Roa6, Raymark Salonga8, Katrina Faith San Gabriel5, Catherine Lynn Silao9,10.   

Abstract

Aim: A case-control study was conducted in Filipino patients to determine the association between HLA alleles and carbamazepine-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). Materials & methods: A retrospective review of medical records and data collection were performed. A total of 10 carbamazepine-induced SJS/TEN cases and 40 tolerant controls were recruited. Genomic DNA extracted from saliva samples was genotyped. Statistical analysis was done.
Results: The HLA-B75 serotype (p = 0.003; odds ratio [OR] = 13.8; 95% CI = 2.5-76.8), HLA-B*15:21 (p = 0.041; OR = 4.7; 95% CI = 1.1-20.8) and HLA-A*24:07 (p = 0.032; OR = 6; 95% CI = 1.2-30.7) were significantly associated with carbamazepine-induced SJS/TEN.
Conclusion: The HLA-B75 serotype, HLA-B*15:21 or HLA-A*24:07 may be used for pharmacogenetic screening prior to prescribing carbamazepine in Filipinos.

Entities:  

Keywords:  Filipino; HLA-A*24:07; HLA-B*15:21; HLA-B75 serotype; Stevens–Johnson syndrome; antiepileptic agent; carbamazepine; human leukocyte antigen; severe cutaneous adverse drug reactions; toxic epidermal necrolysis

Mesh:

Substances:

Year:  2021        PMID: 33910375      PMCID: PMC8191649          DOI: 10.2217/pgs-2020-0191

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.638


  13 in total

1.  HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.

Authors:  Mark McCormack; Ana Alfirevic; Stephane Bourgeois; John J Farrell; Dalia Kasperavičiūtė; Mary Carrington; Graeme J Sills; Tony Marson; Xiaoming Jia; Paul I W de Bakker; Krishna Chinthapalli; Mariam Molokhia; Michael R Johnson; Gerard D O'Connor; Elijah Chaila; Saud Alhusaini; Kevin V Shianna; Rodney A Radtke; Erin L Heinzen; Nicole Walley; Massimo Pandolfo; Werner Pichler; B Kevin Park; Chantal Depondt; Sanjay M Sisodiya; David B Goldstein; Panos Deloukas; Norman Delanty; Gianpiero L Cavalleri; Munir Pirmohamed
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

2.  A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.

Authors:  Christine Lonjou; Nicolas Borot; Peggy Sekula; Neil Ledger; Laure Thomas; Sima Halevy; Luigi Naldi; Jan-Nico Bouwes-Bavinck; Alexis Sidoroff; Claudia de Toma; Martin Schumacher; Jean-Claude Roujeau; Alain Hovnanian; Maja Mockenhaupt
Journal:  Pharmacogenet Genomics       Date:  2008-02       Impact factor: 2.089

3.  HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population.

Authors:  Hiroyuki Niihara; Takeyasu Kakamu; Yasuyuki Fujita; Sakae Kaneko; Eishin Morita
Journal:  J Dermatol       Date:  2011-12-29       Impact factor: 4.005

4.  Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans.

Authors:  Sae-Hoon Kim; Kyung Wha Lee; Woo-Jung Song; Sang-Heon Kim; Young-Koo Jee; Sang-Min Lee; Hye-Ryun Kang; Heung-Woo Park; Sang-Heon Cho; Seong-Ho Park; Kyung-Up Min; Yoon-Seok Chang
Journal:  Epilepsy Res       Date:  2011-09-13       Impact factor: 3.045

5.  Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients.

Authors:  Yan Zhang; Jin Wang; Li-Mei Zhao; Wei Peng; Guo-Qing Shen; Ling Xue; Xiao-Xian Zheng; Xiao-Jing He; Chun-Yan Gong; Li-Yan Miao
Journal:  Eur J Clin Pharmacol       Date:  2011-03-19       Impact factor: 2.953

6.  Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.

Authors:  Shuen-Iu Hung; Wen-Hung Chung; Shiou-Hwa Jee; Wen-Chieh Chen; Yun-Ting Chang; Woan-Ruoh Lee; Shu-Ling Hu; Meng-Tse Wu; Gwo-Shing Chen; Tak-Wah Wong; Pa-Fan Hsiao; Wei-Hsuan Chen; Han-Yu Shih; Wu-Hsiang Fang; Chun-Yu Wei; Yi-Hui Lou; Yau-Li Huang; Juei-Jueng Lin; Yuan-Tsong Chen
Journal:  Pharmacogenet Genomics       Date:  2006-04       Impact factor: 2.089

7.  Rash from antiepileptic drugs: influence by gender, age, and learning disability.

Authors:  Silje Alvestad; Stian Lydersen; Eylert Brodtkorb
Journal:  Epilepsia       Date:  2007-05-01       Impact factor: 5.864

8.  HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Nahoko Kaniwa; Yoshiro Saito; Michiko Aihara; Kayoko Matsunaga; Masahiro Tohkin; Kouichi Kurose; Jun-ichi Sawada; Hirokazu Furuya; Yukitoshi Takahashi; Masaaki Muramatsu; Shigeru Kinoshita; Masamichi Abe; Hiroko Ikeda; Mariko Kashiwagi; Yixuan Song; Mayumi Ueta; Chie Sotozono; Zenro Ikezawa; Ryuichi Hasegawa
Journal:  Pharmacogenomics       Date:  2008-11       Impact factor: 2.533

9.  HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese.

Authors:  Dinh Van Nguyen; Hieu Chi Chu; Doan Van Nguyen; Minh Hong Phan; Timothy Craig; Karl Baumgart; Sheryl van Nunen
Journal:  Asia Pac Allergy       Date:  2015-04-29

10.  HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children.

Authors:  U Amstutz; C J D Ross; L I Castro-Pastrana; M J Rieder; N H Shear; M R Hayden; B C Carleton
Journal:  Clin Pharmacol Ther       Date:  2013-03-18       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.